Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas with complex molecular structures.

At Mayo Clinic, quality is not an act, it’s a habit. This commitment extends into BioPharma Diagnostics, where a team of four quality assurance assistants and three lab processing assistants has recently come together as the BioPharma Accessioning Pod. Their focus includes accommodating the unique requirements of BioPharma clinical trials and research samples during accessioning and sharing data and findings with the BioPharma Diagnostics team.

Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.

The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.

BioPharma Diagnostics executives will attend the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting in Anaheim, California, from July 23–27. They will be available to meet with attendees to discuss how our capabilities and data can accelerate biopharmaceutical and clinical research initiatives.

Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.

BioPharma Diagnostics executives will attend the Drug Information Association (DIA) 2023 Global Annual Meeting in Boston from June 25–29. They will be available to meet with attendees to discuss how our capabilities and data can accelerate biopharmaceutical and clinical research initiatives.

BioPharma Diagnostics executives will attend the American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 2–6. They will be available to meet with attendees to discuss how our capabilities and data can accelerate biopharmaceutical and clinical research initiatives.

Mayo Clinic BioPharma Diagnostics executives will attend the American Association for Cancer Research (AACR) annual meeting in Orlando, Florida, April 14–19. They will be available to meet with attendees to discuss how our capabilities and data can accelerate biopharmaceutical and clinical research initiatives.

Mayo Clinic researchers and collaborators have discovered a critical role that inflammation plays in liver regeneration after liver resection. While effective regeneration requires some inflammation, too much of it causes regeneration failure. They also discovered that patients experiencing dysfunctional liver regeneration had a significantly dysregulated gene known as DUSP4 – a finding that could help support targeted therapeutic strategies administered before or after surgical resection to prevent liver failure.

Mayo Clinic Laboratories has developed a new direct ethanol biomarker test for alcohol consumption that has a much longer detection window than existing urine tests for alcohol use.

Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.